Transaction DateRecipientSharesTypePriceValue
19th October 2020Gene Liau7,225Open or private sale$38.42$277,585.95
19th October 2020Gene Liau24,775Open or private sale$37.64$932,578.07
19th October 2020Gene Liau1,503Exercise of derivative$2.19$3,291.57
19th October 2020Gene Liau30,497Exercise of derivative$0.60$18,298.20
16th October 2020Gene Liau5,851Open or private sale$40.00$234,041.76
16th October 2020Gene Liau5,851Exercise of derivative$0.60$3,510.60
14th October 2020Group, Llc Redmile195,158Open or private purchase$19.20$3,747,580.04
14th October 2020Group, Llc Redmile158,100Open or private purchase$18.01$2,847,665.58
14th October 2020Group, Llc Redmile2,941,176Open or private purchase$17.00$49,999,992.00
14th October 2020Group, Llc Redmile2,178,738Conversion of derivative$0.00
Stoke Therapeutics
Stoke Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.


Ticker: STOK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1623526
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals